体素内不相干运动成像用于骨肉瘤新辅助化疗患者的疗效评估
前瞻性分析40例经病理确诊的骨肉瘤患者,在3周期新辅助化疗前、1周期后和3周期后行1.5T MRI弥散加权成像(11个b值,0-800 s/mm²),采用RECIST1.1评价疗效。定量IVIM参数尤其是D*和f及其直方图分析有信息价值,可作为无创替代标志物用于新辅助化疗过程中的早期疗效评估。
要点
- D*方差和f偏度在化疗期间(t1、t2)在疗效组间有统计学差异(p=0.038、0.003和p=0.03、0.03)。
- t1时D*方差和f偏度联合分类PR组AUC=0.77(敏感度73%,特异度70%),分类SD组AUC=0.74(敏感度74%,特异度75%)。
- D*均值、D*方差、D*熵和f熵的Δ1和Δ2变化与肿瘤直径和体积变化有较好相关性(0.5-0.6)。
核心结论
- 定量IVIM参数尤其是D*和f及其直方图分析有信息价值,可作为无创替代标志物用于骨肉瘤新辅助化疗过程中的早期疗效评估。
研究设计与样本
- 前瞻性分析40例经组织学确诊的骨肉瘤患者(男30例,女10例;年龄17.7±5.9岁;转移17例,局限23例),接受3周期新辅助化疗。
- 所有患者在治疗前(t0)、1周期后(t1)和3周期后(t2)使用1.5T MRI扫描仪行弥散加权成像,采用11个b值(0-800 s/mm²)。
- 采用RECIST1.1标准进行新辅助化疗的无创疗效评估。
关键影像表现/征象
- 新辅助化疗前(t0)肿瘤体积平均ADC、D、D*和f分别为1.36±0.33×10⁻³ mm²/s、1.3±0.3×10⁻³ mm²/s、28.44±10.34×10⁻³ mm²/s和13.95±2.83%。
诊断标准与关键数值
- 采用RECIST1.1标准,部分缓解(PR)11例(27.5%)、疾病稳定(SD)21例(52.5%)、疾病进展(PD)8例(20%)。
- 化疗期间(t1、t2)D*方差(p=0.038、0.003)和f偏度(p=0.03、0.03)在疗效组间有统计学差异;t2时D*熵(p=0.001)和f熵(p=0.002)及其Δ2变化(p=0.001、0.003)有统计学差异。
- t1时D*方差和f偏度联合分类PR组AUC=0.77(敏感度73%,特异度70%),分类SD组AUC=0.74(敏感度74%,特异度75%)。
- D*均值、D*方差、D*熵和f熵的Δ1和Δ2变化与肿瘤直径和体积变化有较好相关性(0.5-0.6)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To explore the role of quantitative Intravoxel incoherent motion (IVIM) parameters and their histogram analysis in characterizing changes in Osteosarcoma receiving neoadjuvant chemotherapy (NACT) and evaluating therapeutic response.
METHODS: Forty patients (N = 40; Male:Female = 30:10; Age = 17.7 ± 5.9years; Metastatic:localized = 17:23) with histologically confirmed Osteosarcoma treated with 3-cycles of NACT were analyzed prospectively. All patients underwent Diffusion weighted imaging (DWI) with 11 b-values (0-800 s/mm2) using 1.5 T MRI scanner at pre-treatment (t0), after 1-cycle (t1) and after 3-cycles (t2) of NACT. Non-invasive response evaluation of NACT was performed using RECIST1.1 criteria. Apparent-diffusion-coefficient (ADC) and IVIM parameters - Diffusion-coefficient (D), Perfusion-coefficient (D*) & Perfusion-fraction (f) and their relative percentage changes from time-point t0-t1 (Δ2) and t0-t2 (Δ2) were evaluated and histogram analysis was performed at three time-points and compared with respect to RECIST1.1 scores.
RESULTS: Using RECIST1.1 criteria, 11 (27.5%), 21 (52.5%) and 8 (20%) patients were in Partial-responder (PR), Stable-disease (SD) and Progressive-disease (PD) groups respectively. Pre-NACT (t0), average ADC, D,D*&f in tumor volume were 1.36 ± 0.33 × 10-3 mm2/s, 1.3 ± 0.3 × 10-3 mm2/s, 28.44 ± 10.34 × 10-3 mm2/s & 13.95 ± 2.83% respectively. Using ANOVA test, during NACT (t1, t2), D*-variance (p = 0.038, 0.003) and f-skewness (p = 0.03, 0.03) and at t2, D*-entropy (p = 0.001) and f-entropy (p = 0.002) and their Δ2 changes (p = 0.001, 0.003) were statistically significant among response groups. At t1, D*-variance and f-skewness jointly showed AUC = 0.77 & 0.74 in classifying PR (Sensitivity = 73%; Specificity = 70%) and SD (Sensitivity = 74; Specificity = 75%) groups respectively in patient cohort. Δ1 & Δ2 changes of D*-mean, D*-variance, D*-entropy and f-entropy correlated well (0.5-0.6) with tumor-diameter and tumor-volume changes.
CONCLUSIONS: Quantitative IVIM parameters, especially D* &f and their histogram analysis were informative and can be used as noninvasive surrogate markers for early response assessment during the course of NACT in Osteosarcoma.
引用
- Baidya Kayal E, Kandasamy D, Khare K, et al. Intravoxel incoherent motion (IVIM) for response assessment in patients with osteosarcoma undergoing neoadjuvant chemotherapy. Eur J Radiol. 2019. PMID: 31445487. doi:10.1016/j.ejrad.2019.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。